Examkin

Question

Difficulty: HardGastroenterology and Hepatology

A 59-year-old man with a history of alcoholic cirrhosis and esophageal varices is hospitalized due to generalized abdominal pain and a low-grade fever. On admission, his temperature is 38.1 °C (100.6 °F), blood pressure is 105/65 mmHg, and heart rate is 98/min. Physical examination reveals scleral icterus, spider angiomata, and a distended abdomen with shifting dullness and diffuse mild tenderness.

A diagnostic paracentesis yields cloudy ascitic fluid with a leukocyte count of 1,200/mm³ and a neutrophil count of 950/mm³. He is immediately started on intravenous albumin and empiric intravenous piperacillin-tazobactam.

On hospital day 3, the patient is afebrile and reports significant improvement in his abdominal pain. Ascitic fluid cultures from admission grow *Klebsiella pneumoniae*. Susceptibility testing indicates the isolate is resistant to ampicillin, but susceptible to ceftriaxone, cefotaxime, ciprofloxacin, and piperacillin-tazobactam. Blood cultures show no growth.

Which of the following is the most appropriate next step in the antimicrobial management of this patient?

  1. De-escalate antimicrobial therapy to intravenous ceftriaxoneAnswer
  2. B
    Continue intravenous piperacillin-tazobactam for a total 14-day course
  3. C
    Escalate antimicrobial therapy to intravenous meropenem
  4. D
    Add intravenous vancomycin to the current regimen
  5. E
    Discontinue all antimicrobial therapy immediately

Answer

De-escalate antimicrobial therapy to intravenous ceftriaxone
The correct action is to de-escalate antimicrobial therapy to intravenous ceftriaxone. This patient's absolute neutrophil count of 950/mm³ confirmed the diagnosis of spontaneous bacterial peritonitis (SBP). While empiric therapy with piperacillin-tazobactam may occasionally be utilized in patients with critical illness or healthcare-associated SBP, antimicrobial stewardship mandates tailoring the regimen once susceptibilities are known. The *Klebsiella pneumoniae* isolate is susceptible to ceftriaxone, a targeted third-generation cephalosporin that is the standard of care for SBP. De-escalating therapy minimizes the ecological pressure for multidrug-resistant organisms while effectively treating the underlying infection.

Step-by-Step Solution

1
Identify the primary diagnosis based on the clinical presentation and initial ascitic fluid analysis.
The patient has Spontaneous Bacterial Peritonitis (SBP), confirmed by an absolute neutrophil count greater than 250/mm³ (950/mm³) in the ascitic fluid.
Accurate diagnosis establishes the baseline severity and directs the initial need for empiric antimicrobial therapy and albumin.
2
Evaluate the patient's clinical trajectory in conjunction with the microbiological culture and susceptibility data.
The patient is clinically improving. Ascitic fluid cultures isolated *Klebsiella pneumoniae*, which is susceptible to ceftriaxone, cefotaxime, ciprofloxacin, and piperacillin-tazobactam.
Integrating clinical response with definitive microbiological data is necessary to adjust empiric therapy to definitive therapy.
3
Apply the principles of antimicrobial stewardship to select the definitive treatment regimen.
De-escalate the current broad-spectrum regimen (piperacillin-tazobactam) to a narrower, targeted agent (ceftriaxone) to complete a typical 5 to 7-day treatment course.
Using the narrowest effective spectrum minimizes toxicity, preserves the normal microbiome, and reduces the risk of generating multidrug-resistant organisms.

Key Concept

In patients with spontaneous bacterial peritonitis who are clinically improving, initial broad-spectrum empiric antibiotics should be de-escalated to targeted, narrow-spectrum therapy (such as a third-generation cephalosporin) as soon as culture and susceptibility results are available, in accordance with antimicrobial stewardship.
Estimated Time:1m 30s
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic